diagnost tool
diagnost tool
price close busi apr
preview buy-rat
buy-rat report result wed may tue
may respect believ underli environ anim health remain
solid favor head print would let print result
ad posit compani look right ship get back track
preview strong prior year comp believ setup
ok model in-lin rev y/i vs guid y/
rep fxn in-lin adj ep y/i vs comp
comp y/i rev though four point revenu growth
due fx benefit organ revenue growth model
consum servic rev y/i refer lab rev
y/i rapid assay rev y/i instrument rev
y/i expect updat revenue guid
rep fxn y/i dx recur revenue guid
roughli match us/street look bounce-back ou refer lab
softer-than-expect look updat idxx adj ep guid
rep fxn line us/th street
key call continu page
custom patient visit data trend deliv growth
recent peak
may learn strength clinic patient visit vs non-clin visit
competit dynam follow acquisit abaxi zoeti believ
combin zts-abax littl impact slight risk
opportun maintain and/or take share corporate-own vet clinic market
preview could make break quarter seem
dismal hope bar low enough admit lack convict
model rev y/i vs street y/i
model lp look cca rev y/i line
street ovp rev y/i street look
vs street om expect chang
revenue guid y/i hska core revenue guid rev
y/i non-cor rev guid y/i
key call continu page
top-lin guid afford guid bar alreadi lower
opex guid expect chang opex guid y/i
time product launch rotor chemistri ou element multiplex
immunodx analyz initi launch cortisol urine-fec
ou expans updat possibl partnership larg establish firm
like tuck-in
look evid ship petvet center
updat lt target rev y/i om requir
y/i margin expans rev om
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
preview ahead
clinic patient visit hold end-us demand remain strong
despit rise on-line channel call indic sampl
custom patient visit deceler recent peak
though clinic patient visit grew
note rise on-line provid like vet first choic petiq
pet owner sourc medic food outsid tradit vet clinic
see threat clinic patient visit dx revenu stream reassur
investor rise prevent care clinic rise millenni -age
pet owner vet new test like sdma sedivu major uptick
util dx test ou mark import revenu growth lever think may
learn split clinic non-clin visit call
see synergi pharma contrari zoeti perspect
see lot synergi anim health diagnost therapeut
fact therapeut divis ridg pharmaceut sold
year ago lack synergi pharma diagnost
believ call point dx typic practic owner treatment
call point often doctor within practic one zoeti lead drug
apoquel often prescrib itchi dog argu diagnost test
diagnos itch limit util mani zoeti treatment
use companion anim rather product anim
model see know fast work pipelin
model rev investor know invest
industri sell-sid estim incorpor valu new revenu
ep associ product yet announc mum product
launch team hard work confid see futur
innov perhap in-clin molecular diagnost higher-throughput next-gen
chemistri hematolog new test on-a-slid possibl sequencing-bas test hit
beyond
role rise anim hospit consolid
mom pop vet clinic shift toward larger corporate-own clinic
estim vet clinic clinic us
corpor ownership decad ago said estim
corpor clinic revenu typic larger clinic
tend test number driver behind shift
increas invest move anim health privat equiti morgan
stanley kkr exampl strateg buyer mar inc huge privat
held player anim health demonstr on-going interest consolid anim
hospit small clinic owner increasingli interest join larger
corporate-own entiti either cash retire/sel busi benefit
share greater economi scale negoti vendor among sever
factor alreadi well-posit larg corpor group though
see opportun take share leverag breadth product
bundl also see opportun busi vca own
mar compet vca antech refer lab howev indic
recent investor meet sinc mar acquir vca antech year ago
competit tension dissip sinc antech lab rel small
percentag mar overal larg pie revenu believ help mar grow
anim health hospit busi across brand bluepearl banfield pet
partner even vca hospit
diagnost tool
call
product development/launch updat look hear manag reiter
timelin plan uf urine/fec instrument launch compani
target remind would mark delay rel time
announc analyst day compani origin commun
urin fecal near term look rollout compani rotor
chemistri analyz ou well element analyz
initi plan roll cortisol
stick buy rate quit disappoint compani updat
mention guid significantli lower
estim call buy thesi remain intact
howev believ thesi challeng given seem on-going
stream disappoint oper result mani facet compani busi
temper expect due weak non-cor busi
segment lower margin assumpt previous announc push-out
compani urine-fec instrument target launch
execut convert larg new custom hope learn
ship petvet center manag indic new
contract win ship much slower expect visibl
instrument ship limit best beyond petvet look updat
ship etho indic corpor vet hospit
us vs nascent chines market point rise interest vet
invest china evidenc acquisit hillhous capit group one
china largest ventur fund chines vet hospit enter
remain corpor site instal total corpor custom
look earn competit contract win similar multi-year hospit suppli
agreement pathway vet allianc hospit petvetcar hospit
etho hospit vitalpet hospit
ou expans recent tuck-in acquisit franc think may learn
signific deal would put europ meaning way
visibl limit term smaller deal close
acquisit optom france-bas compani design develop
manufactur distribut vet imag product primari focu
endoscopi optom gener rev million employe
acquir busi modest sum resourc give
busi beachhead franc see variou opportun
across europ similar other much larger view still
desir partner larg establish firm suspect potenti deal
indic presenc franc
see quit opportun ou bolt tuck-in tune
rev thu think like remain acquisit pay deal
cash remain question us option
financ view recent mention see opportun acquir
revenu one sever possibl deal ou busi
build australia month expect first revenu australia
come also target new partner middl east
ukrain eastern europ select asian countri doesnt coverag
look clariti regard long-term financi target call
reiter long-term target rev y/i om
requir y/i margin expans rev om
diagnost tool
revenu target could hit acquisit fail see
math work realiz long-term om goal
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin april et
date time product april et
price target use multipl revenu estim discount back year discount rate
price target use multipl adj ep estim y/i
risk achiev target price valuat
last sever year achiev meaning multipl expans trade rel similar multipl
competitor abax trade premium multipl slowdown us economi
anim health util could slow revenu margin growth particularli given industri almost self-pay small
penetr health plan insur competit abax particularli abax idexx replic strategi
mirror chang distributor relationship contribut risk associ
busi oversea execut build ou busi consum price time new product launch
abil innov keep industri leader fewer capit resourc smaller compani risk rel competitor
oper refer lab offer product certain new product categori exampl sdma test
thu present posit cross-sel across product well industry-lead abil maintain
expand us market share strong competitor leverag larger budget invest signific new product launch
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
diagnost tool
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
